Pune: The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s Carrying and Forwarding (C&F) unit in Wadki, Pune, following a series of regulatory violations linked to Reactin Plus Tablets, including packaging irregularities, storage deficiencies, stock-record discrepancies and alleged non-compliance with a recall direction.

The cancellation came into effect on August 27, 2026, after inspections of the company’s warehouse and drug distribution operations uncovered multiple lapses. The action has put the spotlight on compliance practices at the pharmaceutical distribution level, particularly for prescription medicines classified under Schedule H.

Cipla, however, has contested the order and said the matter is currently sub judice. The company has also clarified that the FDA’s action does not allege any issue concerning the safety, quality or efficacy of its products and does not indicate a patient safety incident.

Why Did Maharashtra FDA Cancel Cipla’s Pune Drug Licence?

The regulatory action stems from inspections conducted earlier this year, with the initial concerns centred on the packaging of Reactin Plus Tablets.

During an inspection in June, officials reportedly found that the packaging of Reactin Plus, a Schedule H prescription medicine, carried an unauthorised description referring to the product as an “analgesic and antipyretic”. The regulator considered the claim inconsistent with provisions of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

The concern was not limited to the wording itself. According to the FDA, promotional or therapeutic claims on prescription-drug packaging can potentially influence consumers to purchase or use medicines without appropriate medical advice.

The regulator subsequently seized Reactin Plus stock valued at approximately Rs 11.19 lakh and directed that the affected medicines be withdrawn from the market.

Reactin Plus Recall Became a Key Part of the Dispute

The FDA’s concerns deepened when it examined how the company responded to the recall directions.

Following the seizure, the regulator directed the company to recall the affected Reactin Plus tablets. However, officials later concluded that the company had not fully complied with the recall instructions and other corrective measures.

The recall issue became significant because pharmaceutical recalls depend on accurate identification, tracking and withdrawal of affected stock from the supply chain. Any gap between the quantity distributed, the quantity recovered and the inventory recorded by the company can make it difficult for regulators to establish whether a recall has been comprehensively implemented.

In Cipla’s Pune case, the FDA said subsequent inspections identified discrepancies involving purchase records, sales records, computerised inventory and physical stock.

FDA Finds Storage Lapses at Cipla’s Pune Warehouse

The inspection also raised questions about the physical storage of medicines at the Wadki facility.

According to the regulator, some medicines were found stored directly on the floor. Inspectors also flagged inadequate arrangements involving pallets and racks required for proper pharmaceutical storage.

Storage conditions are a critical part of pharmaceutical distribution because medicines must be protected from contamination, damage and unsuitable environmental conditions throughout the supply chain. While the FDA’s action in this case relates to compliance at the distribution facility, the findings underline how regulatory obligations extend beyond manufacturing plants to warehouses and other points through which medicines move before reaching retailers and patients.

The regulator also identified deficiencies in procedures and documentation concerning expired medicines. These findings added another layer to the compliance concerns already surrounding the facility.

Stock Records Did Not Match Physical Inventory

Another major issue highlighted by the FDA involved inventory management.

Officials reportedly found differences between the physical stock available at the facility and the quantities reflected in computerised records. There were also discrepancies involving purchase and sales documentation.

Such records are particularly important when a company is dealing with a product recall. A reliable inventory trail allows regulators and pharmaceutical companies to identify where affected batches have gone, how much stock remains in circulation and whether recalled medicines have actually been removed from the market.

The FDA treated the discrepancies as part of a broader pattern of deficiencies in the drug sale and distribution system operated by the C&F unit.

Show-Cause Notice Issued Before Licence Cancellation

The licence cancellation was preceded by regulatory proceedings, including a show-cause notice issued to the licence holder.

The company was given an opportunity to respond to the violations identified during inspections. After examining the explanation, the FDA concluded that the deficiencies and directions concerning the Reactin Plus recall had not been adequately addressed.

The regulator then proceeded with cancellation of the drug sale licences associated with the Pune C&F unit, with the order taking effect from August 27.

The sequence is important because the licence cancellation was not triggered by a single isolated observation. Rather, the FDA’s decision followed a combination of findings involving product packaging, recall compliance, storage practices, inventory records and procedures for dealing with expired medicines.

Cipla Says No Product Safety or Quality Concern Was Alleged

Cipla has pushed back against interpretations that the action represents a finding that its medicines were unsafe.

The company said the FDA order concerns the operations of a C&F warehouse operated on behalf of Cipla Pharma & Life Sciences and is currently under judicial consideration. It therefore declined to comment in detail on the proceedings.

At the same time, the company specifically clarified that the order does not allege concerns relating to the safety, quality or efficacy of its products. Cipla also said the matter does not involve or indicate any patient safety issue.

The distinction is significant. The regulatory action concerns the licence of a particular drug sale and distribution facility and follows findings about compliance with packaging, storage, documentation and recall requirements. It should not automatically be interpreted as a declaration that Cipla’s broader portfolio of medicines is unsafe.

Why Schedule H Medicines Are Under Greater Scrutiny

The FDA has placed particular emphasis on the regulatory requirements applicable to Schedule H medicines.

Schedule H drugs are prescription medicines and are subject to specific controls governing their sale and use. In the Cipla case, the regulator’s objection to the Reactin Plus packaging was linked partly to the concern that an unauthorised therapeutic claim could encourage consumers to self-medicate.

The issue therefore goes beyond packaging design. For regulators, the language used to describe a prescription medicine can influence how consumers perceive and use it.

Maharashtra FDA Commissioner Tukaram Mundhe has said that there would be no leniency where drug safety and public health are concerned, particularly in relation to the advertising, sale, storage and distribution of Schedule H medicines. He also warned that violations by entities involved in the manufacture and distribution of medicines would attract action under the law.

What the Cipla Pune Action Means for the Pharmaceutical Sector

The cancellation is significant not necessarily because of the size of the affected inventory, but because of the range of compliance issues identified at one distribution facility.

For pharmaceutical companies, regulatory compliance does not end when a medicine leaves the manufacturing unit. Warehousing, inventory management, product labelling, distribution records, expiry management and recall systems are all critical links in the pharmaceutical supply chain.

The Cipla case demonstrates how weaknesses at any one of these stages can trigger regulatory scrutiny, particularly when several deficiencies emerge during connected inspections.

It also highlights the growing importance of traceability. When a product is subject to recall, companies need systems capable of accurately tracking stock from procurement and warehouse movement to sales and eventual withdrawal.

What Happens Next?

The immediate impact of the FDA order is concentrated on Cipla Pharma & Life Sciences’ Pune C&F operations. The company has contested the action, and the matter is currently under judicial consideration.

The next phase is therefore likely to focus on the regulatory and legal proceedings surrounding the licence cancellation, as well as any corrective measures taken by the company in response to the deficiencies identified by the Maharashtra FDA.

For the pharmaceutical industry, the broader takeaway is clear: compliance at warehouses and distribution centres is being treated as an integral part of drug regulation rather than a secondary operational concern.

The Cipla Pune licence action also sends a strong message to companies handling prescription medicines. Accurate records, appropriate storage, lawful product claims and effective recall mechanisms are not merely administrative requirements; they are essential safeguards for maintaining confidence in the medicine supply chain.

As the proceedings continue, attention will remain on how the dispute is resolved and whether the company is able to address the regulatory concerns surrounding its Pune distribution operations.

With input from agencies

Image Source: Multiple agencies

© Copyright 2026. All Rights Reserved. Powered by Vygr Media.